Across TCGA pan-cancer cohorts, SNORD115-17 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated SNORD115-17 data layer compared with 2 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SNORD115-17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNORD115-17 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, STAD, and SKCM are the cancer types where SNORD115-17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.159	0.625	.016	45	view →
STAD	DFS	Tertile	II,III,IV	0.223	0.641	.043	9	view →
SKCM	OS	Tertile	All	1.000	0.329	.027	9	view →
LGG	OS	Tertile	All	0.746	0.909	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SNORD115-17 tumor-vs-normal RNA expression · all SNORD115-17 data types